News

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

The European Medicines Agency (EMA) has recently approved Sirturo (bedaquiline) for conditional use in the European Union for adults suffering from pulmonary MDR-TB.

The press release from Multimedia News Release can be found at:

http://www.multivu.com/mnr/65014-sirturo-treatment-multi-drug-resistant-tuberculosis

Back in December 2012, the same drug was approved by the US Food and Drug Administration. The blog post highlighting that announcement can be found at:

http://dev-wgnd-blog.pantheonsite.io/bedaquiline-receives-accelerated-approval-from-the-fda-for-mdr-tb-rx/

More News
23 Aug 2022
Last week, the PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...